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Genome-wide RNA-Sequencing 
analysis identifies a distinct fibrosis 
gene signature in the conjunctiva 
after glaucoma surgery
Cynthia Yu-Wai-Man1,2, Nicholas Owen2, Jonathan Lees3, Aristides D. Tagalakis4,  
Stephen L. Hart  4, Andrew R. Webster1,2, Christine A. Orengo3 & Peng T. Khaw1,2
Fibrosis-related events play a part in most blinding diseases worldwide. However, little is known 
about the mechanisms driving this complex multifactorial disease. Here we have carried out the first 
genome-wide RNA-Sequencing study in human conjunctival fibrosis. We isolated 10 primary fibrotic 
and 7 non-fibrotic conjunctival fibroblast cell lines from patients with and without previous glaucoma 
surgery, respectively. The patients were matched for ethnicity and age. We identified 246 genes that 
were differentially expressed by over two-fold and p < 0.05, of which 46 genes were upregulated and 
200 genes were downregulated in the fibrotic cell lines compared to the non-fibrotic cell lines. We also 
carried out detailed gene ontology, KEGG, disease association, pathway commons, WikiPathways 
and protein network analyses, and identified distinct pathways linked to smooth muscle contraction, 
inflammatory cytokines, immune mediators, extracellular matrix proteins and oncogene expression. 
We further validated 11 genes that were highly upregulated or downregulated using real-time 
quantitative PCR and found a strong correlation between the RNA-Seq and qPCR results. Our study 
demonstrates that there is a distinct fibrosis gene signature in the conjunctiva after glaucoma surgery 
and provides new insights into the mechanistic pathways driving the complex fibrotic process in the eye 
and other tissues.
Glaucoma is the leading cause of irreversible blindness worldwide and fibrosis is the critical determinant of the 
long-term surgical success after glaucoma surgery. Histopathologic findings of failed fibrotic capsules have indi-
cated a key role of the fibroblast and the production of extracellular matrix components in the pathophysiology 
of fibrotic encapsulation in glaucoma surgery1. However, fibrosis is a complex multifactorial disease and little is 
known about the diverse molecular mechanisms and pathways underlying the fibrotic response. Identifying the 
dysregulated genes will be important in understanding the complex network of signalling pathways driving the 
fibrotic process and in finding potential novel therapeutic targets and biomarkers of disease severity and progno-
sis in fibrotic eye diseases.
It is well established that certain groups of patients, for example Afro-Caribbean people, scar worse than 
others2, 3. However, reliable biomarkers to stratify the risk of scarring and post-surgical fibrosis in the eye and 
other tissues are currently missing. Being able to predict a patient’s risk of scarring according to their genetic 
profile holds great potential to the development of a more personalised and stratified therapy in ocular fibrosis4. A 
major hurdle has been the lack of availability of human tissues for research and the small surgical specimen sizes 
yielding limited amounts and poor quality RNA. RNA-Sequencing (RNA-Seq) is a powerful and highly sensitive 
technology that allows the whole transcriptome to be studied compared to DNA microarrays and also requires 
smaller amounts of RNA5, 6.
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In this study, we have carried out a genome-wide RNA-Seq analysis to compare the gene expression profiles 
of fibrotic and non-fibrotic human conjunctival fibroblast cell lines between patients with and without previous 
glaucoma surgery, respectively. We have also mapped the enrichment of differentially expressed genes to specific 
gene ontology and protein networks, and identified distinct changes in signalling pathways that could contribute 
to the fibrotic process and clinical phenotype.
Results
Patient Demographics. We performed RNA-Sequencing on 10 fibrotic fibroblast (FF3, FF10, FF13, FF14, 
FF15, FF16, FF17, FF18, FF20, FF21) and 7 non-fibrotic fibroblast (NF1, NF4, NF7, NF8, NF9, NF10, NF11) 
cell lines. The patients were matched for ethnicity and age. The majority of patients in both groups were white 
Caucasians: 7 white Caucasians (70%), 1 Asian, and 2 Afro-Caribbeans in the FF group; 6 white Caucasians (86%) 
and 1 Asian in the NF group (Table 1). There were also no statistically significant differences in age between the 
two groups with a mean age of 41.7 ± 17.1 years for FF patients and 52.0 ± 26.5 years for NF patients (p = 0.344).
The FF patients had marked conjunctival fibrosis from previous glaucoma surgeries (mean = 1.7, range = 1 
to 3). The mean central bleb area, maximal bleb area, bleb height, and bleb vascularity were 1.8 ± 1.0, 1.8 ± 1.0, 
1.7 ± 0.8, and 3.7 ± 1.0, respectively. The FF group had worse best-corrected visual acuity with a mean logMAR 
vision of 0.7 compared to 0.3 for the NF group (p = 0.028). The FF patients also had a mean pre-operative intraoc-
ular pressure (IOP) of 19.4 ± 13.0 mmHg while the NF patients had a mean pre-operative IOP of 27.0 ± 7.9 mmHg 
(p = 0.191). All patients had advanced optic disc cupping with a mean cup-disc ratio of 0.9 and 0.8 in the FF and 
NF groups, respectively (p = 0.313).
RNA-Seq analysis identifies a distinct fibrosis gene signature in the conjunctiva. We extracted 
high quality RNA from all the fibroblast cell lines (RNA integrity number equivalent ≥9.8). Table 2 shows the 
total reads sequenced, the intragenic/exonic/intronic/intergenic rates, the number of genes detected, and the 
mean coverage in each sample. We identified a distinct fibrosis gene expression profile in the conjunctiva after 
glaucoma surgery (Fig. 1A). A total of 246 genes were differentially expressed in fibrotic fibroblast (FFs) cell lines 
compared to non-fibrotic fibroblast (NFs) cell lines with more than a two-fold change and which were statisti-
cally significant (p < 0.05; Table S1). Out of the 246 genes, 46 genes were upregulated and 200 genes were down-
regulated in FFs compared to NFs. The reason for the significantly larger number of downregulated compared 
to upregulated genes might be because many genes encoding the large family of extracellular matrix proteins, 
growth factors, signalling molecules, and tumour suppressor genes were significantly downregulated in FFs com-
pared to NFs.
Principal component analysis revealed tight clustering of FFs whereas there was more variability in NFs 
(Fig. 1B). As ethnicity can affect the wound healing response after glaucoma surgery, we also performed an 
additional Caucasian FF-Caucasian NF comparison (Fig. 2). The majority of patients in our cohort were 
white Caucasians and we found a large overlap (175 out of the 246 genes) between the ‘all patients’ and ‘white 
Caucasians’ group comparisons (Table S2).
Gene Ontology Analysis. We next carried out detailed GO (gene ontology) enrichment analysis of the 246 
differentially expressed genes (Table S4). Figure S3 shows the directed acyclic graph (DAG) view of the GO anal-
ysis. Enriched ontology groups shown in red included regulation of smooth muscle contraction, proteinaceous 
extracellular matrix, regulation of secretion, the mitogen-activated protein kinase (MAPK) cascade, and angio-
genesis. For the biological process, smooth muscle contraction and muscle contraction were enriched ontology 
groups (Fig. 3A). The MYOCD gene encodes myocardin, a smooth muscle-specific transcriptional co-activator of 
serum response factor (SRF), and its expression was significantly upregulated in FFs compared to NFs (Table S1). 
The CHRM3 gene encodes a muscarinic acetylcholine receptor M3 that causes smooth muscle contraction and its 
expression was also significantly increased in FFs compared to NFs.
Fibrotic (FF) Non-Fibrotic (NF)
Number 10 7
Age, mean in years ± SD 41.7 ± 17.1 52.0 ± 26.5
Gender (M/F) 5 M/5 F 6 M/1 F
Ethnicity
7 Caucasians 6 Caucasians
1 Asian
1 Asian
2 Afro-Caribbeans
Type of glaucoma
7 POAG 3 POAG
3 congenital
3 secondary
1 congenital
Pre-operative intraocular pressures, mean in mmHg ± SD 19.4 ± 13.0 27.0 ± 7.9
Best-corrected visual acuity, mean in logMAR (range) 0.7 (0 to 1) 0.3 (0 to 0.6)
Cup-disc ratio, mean (range) 0.9 (0.7 to 1.0) 0.8 (0.8 to 0.9)
Anti-glaucoma eye drops, mean (range) 3.2 (0 to 5) 3.9 (3 to 5)
Previous glaucoma surgeries, mean (range) 1.7 (1 to 3) 0
Table 1. Patient demographics for the FF and NF groups.
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For the cellular component, proteinaceous extracellular matrix and secretory granule were enriched ontology 
groups (Fig. 3B). Among the proteinaceous extracellular matrix, the COL6A6 gene and the P4HA3 gene that 
encodes prolyl 4-hydroxylase, a key enzyme in collagen synthesis, were significantly downregulated in FFs com-
pared to NFs. The MMP-10, MMP-12 and MMP-24 genes encode matrix metalloproteinases and their expression 
were also significantly decreased in FFs compared to NFs. The FBLN1 gene encodes the extracellular matrix 
component, fibulin-1, and was significantly downregulated in FFs compared to NFs. For the regulation of secre-
tion, the IL-6 gene was significantly upregulated whereas the IL-33 and CD34 genes were downregulated in FFs 
compared to NFs (Table S4).
For the molecular function, growth factor binding and insulin-like growth factor binding were enriched 
ontology groups (Fig. 3C). The FGFR3 gene encodes the fibroblast growth factor receptor 3 and was significantly 
downregulated in FFs compared to NFs. The IGFBP5 gene encodes insulin-like growth factor-binding protein 
5 and its expression was also significantly decreased in FFs compared to NFs. The WISP2 (CCN5) gene is a new 
transcriptional regulator of the TGFβ signaling pathway and its expression was significantly downregulated in 
FFs compared to NFs. The NOV (CCN3) gene is a negative regulator of CTGF (CCN2) and its expression was also 
significantly decreased in FFs compared to NFs.
KEGG, Disease association, Pathway commons, WikiPathways Analyses. We also performed 
detailed KEGG (Kyoto Encyclopedia of Genes and Genomes), disease association, pathway commons, and 
WikiPathways analyses of the 246 differentially expressed genes (Tables S5 to S8). There were many similarities 
between the GO analysis and the other enrichment analyses. In the KEGG pathway (ECM-receptor interaction 
and metabolic pathways), the COL6A6, COMP and P4HA3 genes were significantly downregulated in FFs com-
pared to NFs (Table S5). In the KEGG pathway (MAPK signalling pathway), the RELB gene was also significantly 
upregulated whereas the FGFR3 and DUSP5 genes were downregulated in FFs compared to NFs.
In the disease association analysis (inflammation), the IL-6 gene expression was significantly increased 
whereas the IL-33 gene expression was decreased in FFs compared to NFs (Table S6). In the disease association 
analysis (neoplasms, cancer or viral infections, breast neoplasms, neuroblastoma), the LMO3, MYB and BIRC3 
oncogenes were also significantly upregulated whereas the WISP2, IGFBP5 and RASSF2 tumour suppressor genes 
were significantly downregulated in FFs compared to NFs.
In addition, in the pathway commons analysis (IGF1 pathway, thrombin/protease-activated receptor path-
way, signalling events), the MYOCD gene was significantly upregulated in FFs compared to NFs (Table S7). In 
the pathway commons analysis (IGF1 pathway, IFN-gamma pathway, IL3-mediated signalling events), the IL-
6, RELB and PPP1R13L gene expression was also significantly increased whereas the DUSP5 and FGFR3 gene 
expression was decreased in FFs compared to NFs.
In the WikiPathways analysis (matrix metalloproteinases), the MMP-10, MMP-12 and MMP-24 genes were 
significantly downregulated in FFs compared to NFs (Table S8). In the WikiPathways analysis (myometrial relax-
ation and contraction pathways), the IL-6 gene expression was also significantly increased whereas the IGFBP5 
gene expression was decreased in FFs compared to NFs.
Sample
Total reads 
sequenced Mapped
Mapped 
unique
Intragenic 
rate
Exonic 
rate
Intronic 
rate
Intergenic 
rate
Genes 
detected
Mean 
coverage-
High
Mean 
coverage-
Medium
Mean 
coverage-
Low
FF3 42023726 37592844 27995882 0.948 0.884 0.065 0.052 15674 376.99 16.37 3.82
FF10 37112186 30779958 22735702 0.926 0.862 0.065 0.073 15421 371.14 12.91 3.24
FF13 18788002 16758670 13529630 0.945 0.884 0.061 0.054 14611 212.97 7.47 1.73
FF14 59651682 54662138 36210246 0.947 0.885 0.062 0.052 16031 532.51 22.87 5.98
FF15 34965998 32923072 24999524 0.948 0.886 0.062 0.052 15355 366.59 14.58 3.41
FF16 45049566 41338508 28216626 0.944 0.854 0.089 0.056 15742 395.65 15.88 3.93
FF17 42367044 38687824 26996622 0.930 0.865 0.066 0.070 15508 408.80 16.06 4.01
FF18 38247446 35096216 22061352 0.932 0.873 0.059 0.068 15612 340.66 12.77 3.01
FF20 45156828 41265828 28362946 0.938 0.872 0.066 0.062 16034 399.06 16.36 3.98
FF21 62590502 54318504 35711252 0.943 0.877 0.065 0.057 16030 506.28 21.60 5.31
NF1 46016224 40107626 28253026 0.926 0.862 0.064 0.074 16032 395.65 16.10 4.07
NF4 39105994 36621378 27604732 0.929 0.871 0.059 0.070 15517 386.04 14.99 3.64
NF7 51543864 47002456 33462460 0.937 0.875 0.062 0.063 16027 444.52 19.48 4.56
NF8 39174808 35558266 26244832 0.925 0.864 0.061 0.075 15803 381.37 14.67 3.54
NF9 44996604 40845860 29106082 0.919 0.855 0.063 0.081 15878 383.28 16.38 3.86
NF10 51037730 45634882 32393242 0.933 0.867 0.066 0.067 15735 466.67 18.78 4.39
NF11 46797824 43182836 31797826 0.938 0.874 0.063 0.062 15951 426.46 18.68 4.24
Table 2. The total reads sequenced, the intragenic/exonic/intronic/intergenic rates, and the number of genes 
detected in each sample are presented here. High, medium, and low mean coverage calculations are based on 
the top 1000, middle 1000, and bottom 1000 expressed transcripts, respectively.
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Protein Network Analysis. We further implemented a novel network analysis method utilising the 
STRING v10 network data to identify clusters of genes showing similar significant sets of gene associations and 
similar patterns of differential expression (Table S9). This strategy allows us to leverage the large amount of infor-
mation held in the STRING database to further characterise the RNA-Seq data by looking for shared neighbour-
hoods in the STRING network that show similar differential expression. Since this network-based method does 
not use discrete groups (pathway groupings)‚ as applied to the standard enrichment approach, it can provide a 
complimentary and more global view on the gene expression changes.
Figure 1. (A) Heat map of differentially expressed genes between FFs and NFs. The 100 genes shown in the 
heat map were selected as being the most significant changes, i.e. sorted by p values with the smallest and most 
significant at the top. The genes were clustered using hierarchical average linkage clustering and euclidean 
distances using the R package for Nonnegative Matrix Factorization (NMF)75. (B) Principal component analysis 
(PCA) was performed using DESeq2 on the regularised log transformed count data.
www.nature.com/scientificreports/
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Like the GO analysis, extracellular organisation and components were also enriched in clusters 2 and 4 of the 
network clustering analysis (Fig. 4). The COL6A6, COMP, PRG4, FBLN1 and P4HA3 genes were significantly 
downregulated in FFs compared to NFs (Table S9). Several matrix metalloproteinases genes (MMP-2, MMP-
10, MMP-14, MMP-15, MMP-24) were also downregulated in FFs compared to NFs. In addition, inflamma-
tory cytokines and immune mediators were enriched in clusters 3 and 6 of the network clustering analysis. The 
IL-6, RELB, PPP1R13L and NFKB2 genes were significantly upregulated in FFs compared to NFs (Table S9). 
Conversely, the IL-33 and CD34 gene expression were significantly decreased in FFs compared to NFs. In cluster 
4, the DUSP5 gene negatively regulates members of the MAPK family that are associated with cellular prolifera-
tion and differentiation and its expression was significantly decreased in FFs compared to NFs.
In cluster 6 of the network clustering analysis, the MYOCD and CHRM3 genes were also significantly upreg-
ulated in FFs compared to NFs (Table S9). In clusters 3 and 4, the FGFR3 and IGFBP5 genes were downregulated 
in FFs compared to NFs. Moreover, we found several genes associated with cancer to be differentially expressed 
in FFs compared to NFs. In cluster 6, the LMO3, MYB, and BIRC3 oncogenes were significantly upregulated in 
FFs compared to NFs. The WISP2, IGFBP5 and RASSF2 genes are tumour suppressor genes and were also signif-
icantly downregulated in FFs compared to NFs in cluster 4 of the network clustering analysis.
Validation by Real-time quantitative PCR. We further validated 11 selected genes that were highly 
upregulated or downregulated in the RNA-Seq analysis using real-time qPCR (Table 3). For the upregulated 
genes, the MYOCD, LMO3, IL-6 and RELB gene expression were significantly increased in the RNA-Seq and 
RT-qPCR results. For the downregulated genes, the PRG4, CD34, IL-33, MMP-10, WISP2, COL6A6 and IGFBP5 
gene expression were significantly decreased in the RNA-Seq and RT-qPCR results.
We also studied the correlation between the RNA-Seq and RT-qPCR analyses and found a strong correlation 
between the two sets of results. The Spearman correlation coefficient (r) was 0.917 (p < 0.001) for the MYOCD 
gene, 0.890 (p < 0.001) for the IL-6 gene, 0.980 (p < 0.001) for the WISP2 gene, 0.730 (p < 0.001) for the RELB 
gene, 0.980 (p < 0.001) for the PRG4 gene, 0.995 (p < 0.001) for the IL-33 gene, 0.958 (p < 0.001) for the CD34 
gene, 0.826 (p < 0.001) for the COL6A6 gene, 0.963 (p < 0.001) for the MMP-10 gene, 0.946 (p < 0.001) for the 
IGFBP5 gene, and 0.885 (p < 0.001) for the LMO3 gene (Fig. 5A to K).
Discussion
Here we present the first genome-wide RNA-Sequencing study in human conjunctival fibrosis. We have studied 
the differentially expressed genes between fibrotic and non-fibrotic primary human conjunctival fibroblast cell 
lines from patients with and without previous glaucoma surgery, respectively. Previous microarray studies in 
the rabbit7 and rat8 eyes have reported 315 and 923 significantly altered genes after glaucoma filtration surgery, 
respectively. There has only been one human study of seven capsules of failed glaucoma valves using the RT² 
Profiler PCR Array, and the authors have found that 39 of the 84 tested genes had more than two-fold differential 
gene expression in three or more of the Tenon’s capsules9. Common genes between the three studies and our study 
include extracellular matrix components and matrix metalloproteinases.
We found that the MYOCD gene was significantly upregulated in FFs compared to NFs. Myocardin is a critical 
cofactor of serum response factor (SRF) in the transcriptional program regulating smooth muscle cell differenti-
ation10, and can activate smooth muscle gene expression in a variety of non-muscle cell types via its association 
with SRF11. Myofibroblasts are contractile smooth muscle-like cells that control tissue repair and remodelling, 
and persistent myofibroblast activation is associated with pathological fibrosis and scarring12–14. Alpha smooth 
muscle actin (αSMA) is also a classical smooth muscle target gene of MYOCD and SRF15, 16, and αSMA expres-
sion upregulates fibroblast contractile activity17. SRF is a master regulator of cytoskeletal gene expression18, 19, 
and the Myocardin-related transcription factor/Serum response factor (MRTF/SRF) pathway has been linked to 
ocular20–22, vascular23, skin24, and lung fibrosis25.
Figure 2. Venn diagram listing shared and unique genes in the ‘all patients’ and ‘white Caucasians’ groups. 
Percentages of patients are shown in brackets.
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Figure 3. Enriched gene ontology groups: (A) Biological process, (B) Cellular component, (C) Molecular 
function. The differentially expressed genes list was analysed using ClueGo in Cytoscape. Gene node shading 
indicates shared associations with each term.
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Figure 4. High-level modules were identified by a network clustering algorithm (see methods) using the 
STRING network data. Redness-fill of a node corresponds to the adjusted p value from the RNA-Seq analysis 
(redder nodes have lower p values). Diamonds correspond to upregulated genes whilst ellipses correspond to 
downregulated genes in FFs compared to NFs. The thickness of the node boundary corresponds to the number 
of drugs available to bind the protein. The GO term most strongly associated with the cluster is shown in the 
label. ECM = Extracellular matrix.
Gene
RT-qPCR RNA-Seq
Fold change 
(FF vs NF) p value
Fold change 
(FF vs NF) p value
MYOCD +30.22** 0.005 +11.45** 0.006
LMO3 +7.11* 0.046 +9.13** 0.003
IL-6 +2.70** 0.001 +3.04*** 0.0003
RELB +1.74* 0.017 +2.14** 0.001
PRG4 −47.62* 0.023 −49.61*** 0.0006
CD34 −28.57* 0.033 −14.75** 0.003
IL-33 −27.78* 0.043 −19.90*** 0.0005
MMP-10 −20.06* 0.018 −16.54*** 0.0003
WISP2 −15.15* 0.027 −8.78** 0.009
COL6A6 −13.39* 0.033 −7.41*** 0.0008
IGFBP5 −6.29* 0.022 −3.94** 0.002
Table 3. Validation of highly upregulated or downregulated genes using real-time quantitative PCR. All mRNA 
values were normalised relative to that of GAPDH and triplicate experiments were performed for each gene. 
Statistically significant differences were expressed as *p < 0.05; **p < 0.01; ***p < 0.001.
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Fetal skin wound healing is scarless and fundamentally different from adult wound healing26–29. Scarless fetal 
wound healing is characterised by decreased levels of potent inflammatory cytokines such as IL-630, and the 
IL-6 gene was significantly upregulated in FFs compared to NFs. Scarless fetal wound healing is also associated 
with high levels of hyaluronic acid27, 28 that increases the expression of proteoglycan 4 (PRG4)31. Similarly, our 
results show that the PRG4 gene was significantly upregulated in NFs compared to FFs. IL-6 controls the effector 
characteristics of various T cell subsets including Th17 cells, Th22 cells32, and also plays an important role in 
Figure 5. The Spearman’s correlation r and corresponding p values of the RNA-Seq and RT-qPCR results were 
performed using the mean values obtained from all samples normalised to either NFs or FFs: (A) MYOCD, (B) 
IL-6, (C) WISP2, (D) RELB, (E) PRG4, (F) IL-33, (G) CD34, (H) COL6A6, (I) MMP-10, (J) IGFBP5, (K) LMO3 
genes.
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trachomatous conjunctival fibrosis33, pulmonary fibrosis34, peritoneal fibrosis35, renal interstitial fibrosis36, and 
cancer-associated fibroblasts37. Conversely, the IL-33 gene was significantly downregulated in FFs compared to 
NFs. IL-33 has a protective effect and reduces cardiac hypertrophy and fibrosis after experimental myocardial 
infarction through ST2 signalling38.
Furthermore, we found that the RELB and PPP1R13L genes were significantly upregulated in FFs compared 
to NFs. The RELB gene is part of the NFkB family, which is a master regulator of inflammation and cell death in 
fibrosis39. The PPP1R13L gene encodes a RELA-associated inhibitor that decreases p53/TP53 function and there-
fore suppresses the subsequent activation of apoptosis40. The DUSP5 gene was also significantly downregulated in 
FFs, and methyl-CpG-binding protein 2 (MeCP2) increases the proliferation of cardiac fibroblasts and fibrosis by 
downregulating DUSP541. In addition, we found that the CD34 gene was significantly upregulated in NFs com-
pared to FFs and human peripheral blood CD34+ cell transplantation can halt liver fibrosis and promote hepatic 
regeneration in chronic liver injury42.
In terms of growth factor binding, the IGFBP5 and FGFR3 genes were significantly downregulated in FFs com-
pared to NFs. Insulin-like growth factor-binding protein 5 (IGFBP5) reduces liver fibrosis in chronic cholangiopa-
thy43. The fibroblast growth factor 9 (FGF9) and 18 (FGF18) also inhibit myofibroblast differentiation in idiopathic 
pulmonary fibrosis and their biological effects are partially driven by FGFR344. The CCN family of genes also repre-
sents matricellular proteins that modify signalling of other molecules, specifically those associated with the extracel-
lular matrix. The NOV (CCN3) and WISP2 (CCN5) genes were both significantly downregulated in FFs compared 
to NFs. NOV (CCN3) is a negative regulator of CTGF (CCN2) and a new endogenous inhibitor of the fibrotic path-
way in an in vitro model of renal disease45. WISP2 (CCN5) is also a novel transcriptional regulator of the TGFβ sig-
nalling pathway46 and inhibits cardiac fibrosis47 as well as cell proliferation and motility in smooth muscle cells48, 49.
In addition, several extracellular matrix components were differentially expressed in FFs compared to NFs. 
The PRG4 and FBLN1 genes encode proteoglycan 4 and fibulin-1, respectively, and were significantly downregu-
lated in FFs and in palmar fascia fibroblasts from patients with Dupuytren’s contracture50. Recombinant human 
PRG4 has anti-fibrotic effects and also decreases αSMA expression in lens epithelial cells activated with TGFβ251. 
Scarless fetal wound healing is characterised by rapid and highly organised collagen deposition27–29 and we found 
a significant upregulation of the COL6A6 gene in NFs. The MMP-10, MMP-12 and MMP-24 genes were also 
significantly downregulated in FFs. The decrease in the MMP-10 gene could be explained by the fact that the 
IL-6 gene was significantly upregulated in FFs and IL-6 decreases MMP-10 gene expression via the JAK2/STAT3 
pathway52.
Fibrosis and cancer also share many cellular and molecular pathophysiological mechanisms, namely genetic 
and epigenetic changes, matrix contraction and remodelling, altered regulation of apoptosis, inflammation, 
and angiogenesis. It could in fact be argued that fibrosis and cancer represent a spectrum of the same disease 
and that fibrotic tissues have an increased risk of becoming cancerous compared to non-fibrotic tissues. Several 
oncogenes (LMO3, MYB, BIRC3) were significantly upregulated in FFs compared to NFs. The LMO3 gene is a 
neuroblastoma-associated oncogene53 that encodes a LIM-domain-only protein involved in self-renewal, cell cycle 
regulation, and metastasis54. The MYB oncogene also plays a key role in cell proliferation and differentiation55 in 
leukaemia56, breast cancer57, and colon cancer58. The BIRC3 gene is an inhibitor of apoptosis protein leading to 
apoptosis evasion59 and a predictor of aggressiveness and therapeutic resistance in glioblastoma59. Moreover, we 
found a significant downregulation of several tumour suppressor genes (IGFBP5, WISP2, RASSF2) in FFs com-
pared to NFs. The IGFBP5 gene is a tumour suppressor gene in melanoma and osteosarcoma60. WISP2 is a negative 
regulator of growth, migration, invasion, and a tumour suppressor in colorectal61, gastric62 and breast cancers63. 
The RASSF2 gene is also a tumour suppressor gene in colorectal cancer64 and oral squamous cell carcinoma65.
We are setting up a fibrosis biobank of conjunctival tissues and fibroblast cell lines and we aim to validate our 
results in larger longitudinal studies in the future. A limitation of our study is that most of the patients in the 
fibrotic and non-fibrotic groups were on several anti-glaucoma eye drops and the effects of these medications on 
the gene expression profile remain largely unknown. This might in fact account for the degree of variability in 
gene expression noted among the NF cell lines. There were also both primary open angle and congenital glau-
coma patients in the FF and NF groups, a lower number of females in the NF group, and the expression data were 
derived from primary fibroblast cell lines instead of the original conjunctival tissues. It is well established that 
Afro-Caribbean patients scar worse than white Caucasian patients. The majority of patients in our cohort were 
however white Caucasians and we found a large overlap of genes between the ‘all patients’ and ‘white Caucasians’ 
group comparisons.
In conclusion, we have identified a distinct fibrosis gene signature in the conjunctiva after glaucoma sur-
gery. We have further mapped the differentially expressed genes to distinct pathways linked to smooth muscle 
contraction, inflammatory cytokines, immune mediators, extracellular matrix proteins, and oncogene expres-
sion. Several of the modules identified also contained potential drug targets that could be used to develop new 
anti-fibrotic treatments in the future. Fibrosis is a complex multifactorial disease and our genome-wide RNA-Seq 
study provides new insights into the mechanistic pathways driving the fibrotic process, as well as potential novel 
therapeutic targets and biomarkers of disease severity, in conjunctival fibrosis and other similar contractile scar-
ring conditions in the eye and other tissues.
Methods
Patient Recruitment. We prospectively recruited glaucoma patients at the Moorfields Eye Hospital 
(London, UK) from September 2014 to September 2015, and collected conjunctival tissues at the time of glau-
coma filtration surgery. All experimental protocols were approved by the London-Dulwich research ethics com-
mittee (REC reference 10/H0808/127) and the institutional approval committee at the University College London 
Institute of Ophthalmology. All the methods were carried out in accordance with the approved guidelines. All 
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patients also gave written informed consent and the study adhered to the tenets of the Declaration of Helsinki. 
The inclusion criteria were: age (over 18 year-old) and patients planned to have glaucoma tube surgery. The exclu-
sion criteria were previous conjunctival surgery other than glaucoma surgery. Patients were divided into 2 groups: 
patients who had previous glaucoma surgery and patients with no previous glaucoma surgery.
Clinical Phenotype. We collected detailed clinical data on each patient, including age, ethnicity, gender, 
best-corrected visual acuity, intraocular pressures, cup-disc ratio, previous glaucoma surgeries, and anti-glaucoma 
medications. We also assessed each patient using the Moorfields bleb grading system. Central and maximal bleb 
areas and bleb height were graded on a scale of 1 to 5 (1 = 0%, 2 = 25%, 3 = 50%, 4 = 75%, 5 = 100%). Bleb vascu-
larity was graded on a scale of 1 to 5 (1 = avascular, 2 = normal, 3 = mild hyperaemia, 4 = moderate hyperaemia, 
5 = severe hyperaemia).
Fibroblast Cell Lines. We established fibrotic fibroblast (FF) and non-fibrotic fibroblast (NF) primary cell 
lines from conjunctival tissues collected from patients with previous glaucoma surgery and patients with no 
previous glaucoma surgery, respectively. The conjunctival tissues were mechanically dispersed and the tissue 
fragments were placed in tissue culture dishes with Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen), 
10% fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine at 37 °C with 5% CO2 
as previously described66. Following outgrowth from the explant, the fibroblasts were trypsinised and cultured 
routinely in the above medium. Fibroblast cell lines in early passages 1–2 were used in the experiments.
RNA Sequencing. The RNA was extracted from each fibroblast cell line using the RNeasy mini kit 
(Qiagen, UK) according to the manufacturer’s instructions. The RNA sequencing was performed at the UCL 
Genomics facility (London, UK) using TruSeq RNA Library Prep kit v2 (http://www.illumina.com/products/
by-type/sequencing-kits/library-prep-kits/truseq-rna-v2.html). RNA quality was measured using Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, USA) and each sample was graded using an RNA integrity num-
ber equivalent (RINe) between 1 and 10. We used 500 ng of total RNA as input, based on quantification by the 
Agilent TapeStation RNA assay. Libraries were multiplexed into a single pool and sequenced across all four lanes 
of an Illumina NextSeq 500. Paired-end sequences of 43 nucleotides were generated after adapter removal.
Differential Expression Analysis. The FASTQ files were assessed for quality control using FASTQC 0.11.2 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). Adapter sequences were removed using Trimgalore 
(0.43) (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Paired-end sequence reads 
were aligned to the human GRCh38.p3 release 82 reference transcriptome and genome using STAR 2.4.2a67. 
Counts were summarised using HTSeq 0.6.168 after read duplicates were marked using Picard MarkDuplicates 
(http://www.broadinstitute.github.io/picard) and subsequently removed using Samtools69. Differential expres-
sion analysis was performed between FF and NF sample groups based on summarised read counts using the 
DESeq2 (1.12.3) package70. Prior to modelling with DESeq2, read counts from the sex chromosomes were 
removed. DESeq2 utilises a negative binomial generalised linear model and normalised sample size through 
the packages median-of-ratios method. Read counts were fit to a model where condition is the factor of interest: 
FF and NF levels. Resulting p values were adjusted for multiple testing, as part of the DESeq2 analysis, using 
Benjamini-Hochberg correction71. Genes with more than a 2-fold change in expression and an adjusted p 
value < 0.05 were denoted as differentially expressed.
Gene Ontology, KEGG, Disease association, Pathway commons, and WikiPathways Analyses. 
We used the list of differentially expressed genes to perform GO (gene ontology), KEGG (Kyoto Encyclopedia of 
Genes and Genomes), disease association, pathway commons, and WikiPathways analyses using WebGestalt72 
and ClueGo73 with Cytoscape74 for visualisation.
Protein Network Analysis. The set of genes that were differentially expressed (with an adjusted p 
value < 0.1) were used to build a sub-graph of the string network (https://string-db.org/). The sub-graph was 
converted into a weighted adjacency matrix, where the weights were derived from the STRING v10 confidence 
score (range 0 to 1000) of a functional association. Diagonal elements of the matrix, i.e. self-similarities, were set 
to a maximum confidence score of 1000. Functional association scores between proteins in the adjacency matrix 
were multiplied by -1 if the genes had opposite directions of expression fold change. A Euclidean distance matrix 
(between each column vector) was then generated between the columns of the adjacency matrix. A low value 
(distance) in the resulting distance matrix indicates that the two genes have similar interaction partners and 
direction of differential expression. We next applied agglomerative clustering to the distance matrix using the 
Ward metric. We assigned a high level function to each cluster by its most significant enrichment, using Fishers 
exact test enrichment (one of: extracellular matrix organisation, extracellular matrix, secreted, immune system 
process, signalling, immune response, response to stress, regulation of secretion by cell, immune system process, 
cell communication). The Function-Gene assignments were obtained from Ensembl-BioMart GO annotations, 
except for ‘secreted’ class, which was obtained from Ensembl-BioMart Signal-P predictions. Visual inspection 
suggested an appropriate number of clusters for further analysis as six, which gave a cophenetic distance of 0.69. 
The clusters were then imported into Cytoscape where the major connected components using the STRING 
interaction data from each cluster were displayed.
Real-Time quantitative PCR. RT-qPCR reactions were performed using a Platinum quantitative PCR 
master mix (ThermoFisher Scientific, Hemel Hempstead, UK) on a CFX Real-Time PCR detection system 
(Bio-Rad, Hemel Hempstead, UK). The Taqman gene expression assays were: MYOCD (Hs00538071_m1), 
IL-6 (Hs00985639_m1), IL-33 (Hs00369211_m1), WISP2 (Hs00180242_m1), PRG4 (Hs00981633_m1), CD34 
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(Hs02576480_m1), RELB (Hs00232399_m1), IGFBP5 (Hs00181213_m1), MMP-10 (Hs00233987_m1), COL6A6 
(Hs01029204_m1), LMO3 (Hs00998696_m1), and GAPDH (Hs02758991_g1) (ThermoFisher Scientific, Hemel 
Hempstead, UK). All mRNA values were normalised relative to that of GAPDH and triplicate experiments were 
performed for each gene. Statistical analysis was performed using the Student’s t-test to calculate statistically 
significant differences and individual p values. The validation of the RNA-Seq data with RT-qPCR was performed 
using the Spearman’s correlation of the mean values obtained from all samples normalised to either NF or FF 
samples. Statistically significant differences were expressed as *p < 0.05; **p < 0.01; ***p < 0.001.
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